Dr Shahrokh F. Shariat

Dr Shahrokh F. Shariat

Professor and Chairman Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Austria

Dr. Shariat is currently professor and chairman of the department of urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.  He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, NY, adjunct professor of urology at the University of Texas Southwestern Medical Center, Dallas, TX, USA, and guest professor at the Faculty of Medicine, Charles University, Prague, CZ.

He has published more than 932 peer-reviewed research papers (Scopus h-index 79, 25693 citations; Google scholar h-index 105, 60514 citations), >300 non-peer-reviewed papers, and 18 book chapters.  He is the holder of four patents stemming from his research into prostate and bladder cancer, and is the recipient of various national and international rewards. He has, for example, received the prestigious Matula Award from the European Urological Association and the Gold Cystoscope 2017 from the American Urological Association.  

He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials.  He is a member of various academic societies and a journal, meeting abstract, and grant reviewer for numerous national and international organizations.  He is an editorial board member of various journals including European Urology, BJU International, World Journal of Urology, Current Opinion in Urology (editor in chief), and Immunotherapy among others.  He heads a medical charity for refugees and is on the medical advisory board for two other charities.

His research focuses on urologic oncology – molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research.  Specially, Dr. Shariat’s has been working on the discovery, testing, and validation of molecular markers associated with the biological and clinical behavior of prostate and urothelial cancers. His laboratory research focuses on integrative genomics and epigenomics of urothelial carcinoma with the goal of designing personalized therapeutic strategies.